Stock CMIIU CM LIFE28
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

CM LIFE28 Stock Nasdaq

Equities

CMIIU

US1258422039

Chart CM LIFE28

Dynamic Chart

Latest news about CM LIFE28

Standard BioTools Inc.(NasdaqGM:SLGC) dropped from S&P Global BMI Index CI
Standard BioTools Inc.(NasdaqGM:SLGC) dropped from S&P TMI Index CI
Somalogic, Inc. Provides Revenue Guidance for Fourth Quarter and Full Year 2023 CI
Declaration of Voting Results by SomaLogic Inc CI
Declaration of Voting Results by SomaLogic Inc CI
Declaration of Voting Results by SomaLogic Inc CI
Declaration of Voting Results by SomaLogic Inc CI
Declaration of Voting Results by SomaLogic Inc CI
Standard BioTools Says Merger With SomaLogic Completed MT
SomaLogic, Standard BioTools Receive Shareholder Approvals for Pending Merger MT
SomaLogic, Inc.(NasdaqGM:SLGC) dropped from NASDAQ Composite Index CI
Madryn Asset Addresses SomaLogic?s Failure to Obtain Requisite Shareholder Support for the Proposed Merger with Standard BioTools CI
Madryn Asset Management, LP Sends an Email to Stockholders in Connection with Somalogic, Inc.?s Special Meeting of Stockholders CI
Madryn Asset Management Sent a Letter to the Delaware Court of Chancery CI
Madryn Asset Provides Information to the Shareholders CI
More news

Latest transcript on CM LIFE28

Logo CM LIFE28
SomaLogic, Inc., Q3 2023 Earnings Call, Nov 08, 2023
More transcripts

Analyst Recommendations on CM LIFE28

Jefferies Downgrades SomaLogic to Hold From Buy, Adjusts Price Target to $2.30 From $3.50 MT
Canaccord Genuity Downgrades SomaLogic to Hold From Buy, Cuts Price Target to $2.50 From $5 MT
Canaccord Genuity Adjusts Price Target on SomaLogic to $5 From $6, Maintains Buy Rating MT
Stifel Nicolaus Adjusts SomaLogic Price Target to $8 From $12, Maintains Buy Rating MT
Cowen Adjusts SomaLogic's Price Target to $9 From $11, Keeps Outperform Rating MT
More recommendations

Press releases CM LIFE28

Standard BioTools Stockholders Approve Merger with SomaLogic AQ
SomaLogic Stockholders Vote to Approve Standard BioTools Transaction at Special Meeting PR
Madryn Asset Management Demands SomaLogic’s Board Address Repeated, Unprecedented Adjournments of Tainted Special Meeting BU
Madryn Asset Management Addresses SomaLogic’s Apparent Failure to Obtain Requisite Shareholder Support for the Proposed Merger with Standard BioTools BU
Proxy Advisory Firm Egan-Jones Recommends SomaLogic Shareholders Vote Against Proposed Merger with Standard BioTools BU
More press releases

Company Profile

CM Life Sciences II Inc. is a blank check company. The Company is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The Company has not selected any specific business combination target and has not engaged in any substantive discussions, directly or indirectly, with any business combination target. The Company is engaged in pursuing an initial business combination target in any industry, sector or geographic region. It intends to focus on the life sciences sector. The Company neither engages in any business operations nor generates any revenues.
Sector
-
Calendar
2024-05-08 - Q1 2024 Earnings Release (Projected)
Related indices
Russell 2000
More about the company
  1. Stock Market
  2. Equities
  3. SLGC Stock
  4. CMIIU Stock